2-(3-fluoro-4-methyl-benzyl)-3-oxo-butyric acid ethyl ester | 421592-79-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-fluoro-4-methyl-benzyl)-3-oxo-butyric acid ethyl ester
• 英文别名: ethyl 2-[(3-fluoro-4-methyl) benzyl]-3-oxobutyrate；ethyl 2-[(3-fluoro-4-methyl)benzyl]-3-oxobutylate；Ethyl 2-[(3-fluoro-4-methylphenyl)methyl]-3-oxobutanoate
• CAS: 421592-79-2
• 化学式: C₁₄H₁₇FO₃
• 分子量: 252.286
• InChiKey: ZIVHGAUXKFEPMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-fluoro-4-methyl-benzyl)-3-oxo-butyric acid ethyl ester 在 肼 作用下， 以 甲苯 为溶剂， 生成 1,2-dihydro-4-[(3-fluoro-4-methylphenyl) methyl]-5-methyl-3H-pyrazole-3-one
  参考文献：
  名称：

  Pyrazole derivatives and diabetic medicine containing them

  摘要：

  本发明提供了以下式表示的吡唑-O-糖苷衍生物，用作糖尿病药物。

  公开号：

  US20040006025A1
• 作为产物：
  描述：

  3-氟-4-甲基苯甲醛 以82%的产率得到2-(3-fluoro-4-methyl-benzyl)-3-oxo-butyric acid ethyl ester
  参考文献：
  名称：

  NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME

  摘要：

  公开号：

  EP1338603B1

文献信息

• Prophylactic and therapeutic agent of diabetes mellitus
  申请人：Maezono Katsumi

  公开号：US20050143424A1

  公开（公告）日：2005-06-30

  The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

  本发明提供了一种糖尿病的预防和治疗剂，包括肾脏葡萄糖重吸收抑制剂和降糖剂的组合。根据本发明，可以改善餐后、餐间和禁食期间的高血糖。更具体地，根据本发明，可以实现糖尿病的治疗效果，这是以往相关艺术中的降糖药物所未曾达到的。
• Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives
  申请人：Himmelsbach Frank

  公开号：US20070072813A1

  公开（公告）日：2007-03-29

  The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种预防或治疗代谢性疾病的方法，改善血糖控制，预防从糖耐量受损、胰岛素抵抗和/或代谢综合征进展到2型糖尿病，预防或治疗糖尿病并发症，减轻体重，预防或治疗胰岛β细胞退化，治疗高胰岛素血症和胰岛素抵抗以及1型糖尿病，方法是通过给需要的患者口服含有在权利要求1中定义的吡唑烷-O-糖苷或其前药或其药学上可接受的盐的药物组成物。
• PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE
  申请人：Pinnetti Sabine

  公开号：US20100317575A1

  公开（公告）日：2010-12-16

  The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  本发明涉及一种制药组合物，包括根据权利要求1所述的化合物（1）至（29）中选择的吡唑-O-葡萄糖苷衍生物，与至少一种第二治疗剂的组合物，该第二治疗剂适用于治疗或预防选择自1型糖尿病、2型糖尿病、糖耐量受损和高血糖等一个或多个疾病。此外，本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。
• PREVENTIVE/REMEDY FOR DIABETES
  申请人：Ajinomoto Co., Inc.

  公开号：EP1500403A1

  公开（公告）日：2005-01-26

  The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

  本发明提供了一种预防和治疗糖尿病的药物，包括肾葡萄糖重吸收抑制剂和降糖药的组合。根据本发明，可改善餐后、餐间和空腹时的高血糖症状。更具体地说，根据本发明，可以达到相关技术中的降糖药从未达到过的糖尿病治疗效果。
• New pyrazole derivatives and diabetic medicine containing them
  申请人：Ajinomoto Co., Inc.

  公开号：EP2163555A1

  公开（公告）日：2010-03-17

  The invention provides a pyrazole derivative of formula 1A or 1B which is useful in treating diabetes: wherein X represents a β-D-glucopyranosyl group, of which one or more hydroxyl groups may be acylated or β-D-glucuronyl group, of which one or more hydroxyl groups may be acylated and carboxyl group may be esterified; Y represents a lower alkyl group or perfluoro lower alkyl group; Z represents a hydrogen atom, lower alkyl group, perfluoro lower alkyl group, aralkyl group or phenyl group; R1 to R5 may be the same or different and represent a hydrogen atom, lower alkyl group, perfluoro lower alkyl group, lower alkoxy group, perfluoro lower alkoxy group, lower alkylthio group, perfluoro lower alkylthio group, lower alkyl amino group, halogeno group, lower alkanoyl group, lower alkenyl group or lower alkynyl group, and n represents an integer from 0 to 3; wherein the term "lower" indicates 1 to 6 carbon atoms.

  本发明提供了一种可用于治疗糖尿病的式 1A 或 1B 的吡唑衍生物： 其中X代表β-D-吡喃葡萄糖基，其中一个或多个羟基可被酰化，或代表β-D-葡萄糖醛酸基，其中一个或多个羟基可被酰化，羧基可被酯化；Y代表低级烷基或全氟低级烷基；Z代表氢原子、低级烷基、全氟低级烷基、芳基或苯基；R1 至 R5 可以相同或不同，代表氢原子、低级烷基、全氟低级烷基、低级烷氧基、全氟低级烷氧基、低级烷硫基、全氟低级烷硫基、低级烷基氨基、卤素基、低级烷酰基、低级烯基或低级炔基，n 代表 0 至 3 的整数；其中 "低级 "一词表示 1 至 6 个碳原子。